Jefferson University Hospitals

Physician Profile

Russell Schilder, MD

Jefferson University Physician

Academic Title: Professor
Medical Oncology Director, Gynecologic Oncology Program

Specialties
Medical Oncology
Medical Oncology - Gynecologic Cancer

Make An Appointment

Click to call 1-800-JEFF-NOW (800-533-3669) or

Office Locations

Philadelphia
925 Chestnut Street
Suite 320A
Philadelphia PA 19107
Phone: (215) 955-8874
Fax: (215) 503-7697
Abington
1200 Old York Road
1 Widener - AMH
Abington PA 19001
Phone: (215) 885-0220
Fax: (215) 876-0740

Medical Services

Board Certifications

  • Medical Oncology
  • Hematology
  • Internal Medicine

Hospital Affiliation / Admitting Privileges

  • Thomas Jefferson University Hospital

Awards and Honors

Philadelphia Magazine's Top Docs 2016,2015,2014,2013,2012

Notes

Dr. Schilder specializes in Cervical, Endometrial, Ovarian and Uterine Cancer.

Education

  • University of Miami School of Medicine, Medical School

Internship

  • Temple University Hospital

Residency

  • Temple University Hospital

Fellowship

  • Temple University Hospital

Recent Publications

A phase I pharmacokinetic study of intraperitoneal bortezomib and carboplatin in patients with persistent or recurrent ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study

Ovarian Cancer: New Targets and Future Directions

A randomised, open-label, phase 2 study of the IDO1 inhibitor epacadostat (INCB024360) versus tamoxifen as therapy for biochemically recurrent (CA-125 relapse)-only epithelial ovarian cancer, primary peritoneal carcinoma, or fallopian tube cancer

Hereditary ovarian cancer: Not only BRCA 1 and 2 Genes

Aurora kinase A mediates epithelial ovarian cancer cell migration and adhesion

Refractory fallopian tube carcinoma - Current perspectives in pathogenesis and management

A phase II evaluation of AMG 102 (rilotumumab) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: A Gynecologic Oncology Group study

Adjuvant vaginal cuff brachytherapy for high-risk, early stage endometrial cancer

A phase 1b study of trebananib in combination with pegylated liposomal doxorubicin or topotecan in women with recurrent platinum-resistant or partially platinum-sensitive ovarian cancer

Potential role of mTORC2 as a therapeutic target in clear cell carcinoma of the ovary

A phase II evaluation of motesanib (AMG 706) in the treatment of persistent or recurrent ovarian, fallopian tube and primary peritoneal carcinomas: A Gynecologic Oncology Group study

Influence of bevacizumab on vaginal cuff evisceration eight months after ovarian cancer cytoreduction surgery: A case report

A phase i trial of tailored radiation therapy with concomitant cetuximab and cisplatin in the treatment of patients with cervical cancer: A gynecologic oncology group study

Phase II evaluation of dasatinib in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: A gynecologic oncology group study

Epithelial-to-mesenchymal transition and cellular membrane receptors in ovarian cancer: Moving forward in the era of molecularly targeted therapy

A phase II evaluation of bortezomib in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: A Gynecologic Oncology Group study

mTOR is a promising therapeutic target both in cisplatin-sensitive and cisplatin-resistant clear cell carcinoma of the ovary

A Phase II trial of erlotinib in recurrent squamous cell carcinoma of the cervix

Management of Recurrent Ovarian Carcinoma: Current Status and Future Directions

Phase II trial of single agent cetuximab in patients with persistent or recurrent epithelial ovarian or primary peritoneal carcinoma with the potential for dose escalation to rash